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Abstract
Background: We describe the impact of methicillin-resistant Staphylococcus aureus (MRSA) in two neighbouring regions in
Europe with a comparable population size, North Rhine-Westphalia (NRW) in Germany and the Netherlands.
Methodology/Principal Findings: We compared the occurrence of MRSA in blood cultures from surveillance systems. In the
Netherlands in 2009, 14 of 1,510 (0.9%) Staphylococcus aureus bacteraemia episodes under surveillance were MRSA.
Extrapolation using the number of clinical admissions results in a total of 29 MRSA bacteraemia episodes in the Netherlands
or 1.8 episodes per 1,000,000 inhabitants. In 2010 in NRW, 1,029 MRSA bacteraemias were reported, resulting in 57.6
episodes of MRSA bacteraemia per 1,000,000 inhabitants: a 32-fold higher incidence than in the Netherlands.
Conclusion/Significance: Based on an estimated attributable mortality of 15%, the Dutch approach would save
approximately 150 lives per year by the prevention of bacteraemia only.
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Introduction
Staphylococcus aureus (S. aureus) is a member of the commensal
flora of the skin and mucous membranes. It is also known to cause
serious infections, mostly in hospitalized patients, especially those
undergoing dialysis or surgical procedures [1]. Methicillin-resistant
S. aureus (MRSA) is resistant to beta-lactam antibiotics (penicillins,
cephalosporins and carbapenems), and is a public health concern
in many countries all over the world.
At first, MRSA emerged in hospitals (hospital-associated: HA-
MRSA), but more recently community-associated MRSA (CA-
MRSA) emerged and caused illnesses of varying severity outside
the hospitals. In 2005, MRSA was first linked to livestock and a
genetically distinct group of strains was identified as livestock-
associated MRSA (LA-MRSA) [2]. Nowadays, the boundaries
between HA-MRSA and CA-MRSA have become less clear and
LA-MRSA has entered the arena. MRSA infections are superim-
posed on the existing infections caused by methicillin-susceptible S.
aureus (MSSA) and thereby add significantly to the total burden of
disease [3].
Within Europe marked inter-country variations exist for the
prevalence of MRSA, which can be due to differences in control
measures, usage of antimicrobials and numerous other factors
[4,5]. With this study, we describe the large impact of MRSA in
two neighbouring and almost equally large populated regions,
North Rhine-Westphalia (NRW) in Germany and the Nether-
lands, by comparing the occurrence of MRSA in blood culture
isolates.
Methods
Ethics statement
This study made use of available data, retrieved by national or
regional surveillance programs. Therefore no additional ethical
approval for this study was needed.
The Netherlands
The study was based on data from the national antibiotic
resistance surveillance system in the Netherlands (ISIS-AR) [6].
The 22 participating laboratories serve approximately 50% of all
hospital beds. Data from 2009 on S. aureus isolates were extracted
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and evaluated for material of origin; blood isolates were used, as
these are objective markers of invasive infections. Only the first
blood isolate per patient was included.
In order to compare data from the Netherlands with NRW,
extrapolation of MRSA blood cultures from ISIS-AR to the whole
of the Netherlands was performed using the proportion of clinical
admissions, which were extracted from mandatory annexes from
annual reports on 2009 (Available: www.jaarverslagenzorg.nl.
Accessed 2012 Feb 6.), excluding one-day and psychiatric
admissions. The annexes were only mandatory in 2009, therefore
this year was used to compare data from the Netherlands with
NRW. Clinical admissions were added up and compared to the
national number of clinical admissions in 2009 (Statistics Nether-
lands. Available: www.cbs.nl. Accessed 2012 Feb 6.), excluding the
same two categories.
In order to show the number of MRSA bacteraemia episodes
per 1,000,000 inhabitants, population numbers of the Netherlands
were derived from Statistics Netherlands (Available: www.cbs.nl.
Accessed 2012 Feb 6.). Extrapolation was done under the
assumption that the relation between clinical admissions and
population density is the same for laboratories participating in the
study and for those who do not.
North Rhine-Westphalia (Germany)
Data from NRW in 2010 were collected from the mandatory
reporting of MRSA blood culture isolates from laboratories (State
Institute for Health and Work of the state North Rhine-
Westphalia. Available: www.liga.nrw.de. Accessed 2011 Nov 9.),
which comprises data from all 404 hospitals in NRW. The year
2010 was the first complete year, and this year was used to
compare data from NRW with the Netherlands.
The population number of NRW in 2010 was derived from
North Rhine-Westphalian company for Information and Technics
(Available: www.it.nrw.de. Accessed 2011 Nov 9.).
Results
The Netherlands
Data from 2009 from the 22 participating labs in ISIS-AR
resulted in 1,512 episodes of S. aureus bacteraemia. Of the 1,510
bacteraemia episodes with resistance information, 14 were
methicillin resistant (0.9%). Of the patients with MRSA bacter-
aemias, 79% were male and 71% were older than 65 or younger
than two years of age. The median age was 69 years (interquartile
range 56–74).
The sum of clinical admissions from hospitals belonging to the
participating laboratories in ISIS-AR in 2009 was 903,623, which
is 48% of the total of 1,899,000 admissions in the Netherlands.
Extrapolating the 14 episodes of MRSA bacteraemia in 2009 to
the whole of the Netherlands using the proportion of clinical
admissions, there would have been 14*(1,899,000/903,623) = 29.4
episodes of MRSA bacteraemia in 2009 in the Netherlands in
total. This can be recalculated into an incidence of 29.4/
16,485,787= 1.8 MRSA bacteraemic episodes per 1,000,000
inhabitants in 2009.
Figure 1. Map of the Netherlands (NL) and North Rhine-Westphalia (NRW). MRSA bacteraemia episodes per 1,000,000 inhabitants for the
years 2009 (NL) and 2010 (NRW). A large difference in MRSA bacteraemia episodes was found in this study. Inlay: position of NL and NRW in Europe.
Copyright d-maps.com (used maps: paybas22, rhenanienord38, europemax09).
doi:10.1371/journal.pone.0042787.g001
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North Rhine-Westphalia (Germany)
Data from the mandatory reporting of MRSA blood culture
isolates from 01 January 2010 to 31 December 2010 comprising all
404 hospitals in NRW resulted in 1,029 episodes of MRSA
bacteraemia. This can be recalculated into an incidence of 1,029/
17,872,763= 57.6 MRSA bacteraemias per 1,000,000 inhabitants
of NRW, which is 32-fold higher than in the Netherlands (57.6/
1.8 = 32.0, Fisher exact p,0.0001, Figure 1). Of the patients with
MRSA bacteraemia, 61% were male and 74% were older than 65
or younger than two years of age. The median age was 73 years
(interquartile range 65–80).
Discussion
This study found a large difference in the incidence of MRSA
bacteraemias between the region of North Rhine-Westphalia in
Germany and the Netherlands. NRW had approximately 1,000
episodes of MRSA bacteraemia more in 2010 than the Nether-
lands in 2009 (1,029229.4 = 999), which resulted in a 32-fold
higher incidence of MRSA per 1,000,000 inhabitants. The best
explanations for this difference in incidence of MRSA bacteraemia
in these two adjoining regions with comparable inhabitant
numbers are differences in healthcare structure and differences
in the implementation of an MRSA control strategy.
Healthcare structure differences
The differences in healthcare structure can be illustrated with
several examples. First, there are grossly 3 times more hospitals in
NRW (413 compared to 115 in 2009 in NRW and the
Netherlands, respectively), and about twice as much hospital beds
(6.8 and 3.3 per 1,000 inhabitants in 2009 in NRW and the
Netherlands, respectively) (Statistics Netherlands. Available: www.
cbs.nl. Accessed 2012 Feb 6, State Information and Techniques
North Rhine-Westphalia. Available: www.it.nrw.de. Accessed
2011 Nov 9, EUROSTAT. Available: http://epp.eurostat.ec.
europa.eu/portal/page/portal/eurostat/home/. Accessed 2012
Feb 6.).
Second, in NRW 2.3-fold more patients are admitted to the
hospital compared to the Netherlands, while the length of stay is
comparable (EUROSTAT. Available: http://epp.eurostat.ec.
europa.eu/portal/page/portal/eurostat/home/. Accessed 2012
Feb 6.). More frequent (re)admissons in combination with a
higher MRSA proportion among S. aureus isolates (26.6% for
NRW [7] versus 1.6% for the Netherlands, this study) may lead to
a higher introduction rate of MRSA in hospitals in NRW,
however this does probably not fully explain the large 32-fold
difference in MRSA bacteraemia episodes in this study.
Third, in Germany there are mainly large commercial
laboratories that serve large areas, few hospitals have clinical
microbiologists available on site. In the Netherlands clinical
microbiology laboratories including microbiologists are present in
almost every hospital. They are actively involved in the infection
control strategy. Recently, in Germany a new law was accepted
that made the presence of microbiologists in hospitals mandatory,
which might lead to improvements in infection control. It seems
that the implementation of an MRSA control policy is more
effective in a healthcare structure like the Netherlands.
MRSA control strategy differences
The ‘search and destroy’ (S&D) strategy in the Netherlands
consists of active screening and pre-emptive isolation of persons
admitted to foreign hospitals in the previous two months, persons
previously positive for MRSA, and persons in contact with live
pigs or veal calves (for complete national guidelines see www.wip.
nl). Individuals that carry MRSA are actively decolonized with the
exception of those who have livestock contact [8]. When
unexpected cases are found, active contact tracing is performed.
In Germany there are recommendations actually more strict
than the Dutch strategy, with an extra risk group of persons
admitted to local hospitals in the last 12 months (for complete
German guidelines, see www.rki.de). However, up to now a
complete implementation in Germany has only been shown in
several regional MRSA-networks (www.eursafety.eu, www.mre-
net.org), other regions (among which parts of NRW) have not fully
implemented the screening and isolation strategy. This is in
contrast to the Netherlands, where the S&D strategy is fully
implemented in all hospitals and controlled by the independent
national health inspectorate.
The effectiveness of screening regimens depends on various
factors, such as the number of patients admitted and re-admitted,
the patient-health-care worker ratio [9], the existence of and
adherence to hygiene protocols to prevent transmission [10], and
host susceptibility [4]. Several articles have studied the effect of
individual screening interventions (see [11] for an overview), but so
far the effectiveness of the total bundle of the S&D strategy has not
been tested. The presence of fully implemented proper national
guidelines in all healthcare institutions might be the key to MRSA
infection control.
MRSA prevalence, antimicrobial use and population
characteristics
Other factors that may contribute to a higher incidence of
MRSA bacteraemia are the prevalence of MRSA in the general
population, antimicrobial use and population characteristics.
Germany has on average 2.5 MRSA cases per 100 inpatients, in
contrast to 0.2 MRSA cases per 100 inpatients in the Netherlands
[12,13,14,15]. Moreover, as previously stated, of all S. aureus blood
isolates in NRW in 2009, 26.6% were MRSA [7], compared to
1.6% in the Netherlands (this study).
Additionally, antimicrobial consumption in ambulatory care in
NRW is 16.2 defined daily doses (DDD) per 1,000 inhabitants per
day, as opposed to 11 DDD in the Netherlands (ESAC country
sheets 2008. Available: www.esac.ua.ac.be. Accessed 2012 Feb 6,
Germap 2008. Available: www.bvl.bund.de. Accessed 2011 Nov
9.).
Lastly, when looking at population characteristics or cultural
factors [4,5], the gender and age of patients did not differ between
the regions (79% and 61% males, Fisher exact p = 0.29, and 71%
and 74% persons older than 65 or younger than two years of age,
Fisher exact p= 1.00, in the Netherlands and NRW, respectively).
Study limitations
This study made use of available data, which bares some
limitations. First, selection bias may count for part of the results. In
the region of NRW all MRSA blood cultures are supplied, as for
the Netherlands only about 50% of admissions are covered,
leading to the need to extrapolate these data. The missing hospitals
are relatively often located in the larger cities. If hospitals in large
cities would have more MRSA bacteraemia episodes, for example
because of more foreign patients, patients that travel more often or
more complicated patients, the results of this study would
underestimate the true MRSA bacteraemia prevalence, and
thereby overestimate the difference between the regions studied.
On the other hand, the participating laboratories are located more
often in pig dense areas where MRSA carriage rates are higher
than elsewhere in the Netherlands, hypothetically leading to an
overestimation of MRSA bacteraemia prevalence and an under-
estimation of the difference between the studied regions. However,
MRSA Bacteraemia in The Netherlands and Germany
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LA-MRSA carriage does not often result in bacteraemias.
Regardless of the above, other studies do not indicate that there
are large differences in MRSA prevalences in hospitals within the
Netherlands [4,15]. Therefore we assume that our extrapolation is
legitimate.
A second limitation of this study is the difference in time periods
that were studied (2009 in the Netherlands and 2010 in NRW, for
argumentation see Methods). No major legislational changes have
been described for both countries, and MRSA prevalences are
estimated to be roughly stable over these years [7,16]. For these
reasons we feel that comparison of these two different years is
justifiable.
Third, the effects found in this study could be an underestima-
tion since only bacteraemias were counted. If all MRSA-infections
were included, the morbidity, mortality and costs saved will
probably be more than demonstrated hereunder. So these
assessments can be considered a minimal estimate of the benefits.
Possible effects
The possible impact of the observed differences can be estimated
based on several assumptions. MRSA bacteraemia increases the
burden of disease as it does not appear to replace the susceptible
strains, but comes on top of it [17,18]. This would mean that the
Dutch approach prevents approximately 1,000 MRSA bacteraemia
episodes per year, not only possibly resulting in less morbidity, but
also in less mortality and less costs. Several studies show that the
attributable one-year mortality of MRSA bacteraemia has a lower
limit of 15% (Duin Van D, Fraser T, Jain A, Gordon S, Shresta N.
Attributable mortality after S. aureus bacteraemia. Oral presentation
at the annual scientific meeting of the Society of Healthcare
Epidemiology of America 2011, abstract 299. Available: http://
shea.confex.com/shea/1/webprogram/Paper4403.html. Accessed
2012 Feb 6.) [18,19,20]. Extrapolating these numbers results in a
minimum estimate of 1,000*15%=150 deaths that would not occur
in the Netherlands because of MRSA bacteraemia. According to a
recent mathematical model it will also save money as MRSA
bacteraemia is associated with substantial costs [21].
Conclusions
In conclusion, we observed a huge difference in the incidence of
MRSA bacteraemia episodes in two comparable and neighbour-
ing regions, North Rhine-Westphalia in Germany and the
Netherlands. The estimated annual savings for The Netherlands
are at least 150 lives. Next to differences in healthcare structure,
the active ‘search and destroy’ strategy in the Netherlands appears
to be an efficient way to prevent many MRSA infections.
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